QNCX RSI Chart
Last 7 days
-5.3%
Last 30 days
-10%
Last 90 days
-29.7%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 16, 2024 | thye dirk | acquired | 190,791 | 0.793211 | 240,530 | chief executive officer |
Dec 14, 2023 | lamond david | bought | 23,532 | 1.04 | 22,627 | - |
Dec 13, 2023 | lamond david | bought | 22,627 | 1.00 | 22,627 | - |
Dec 12, 2023 | lamond david | bought | 22,773 | 1.02 | 22,327 | - |
Dec 12, 2023 | lamond david | bought | 300 | 1.00 | 300 | - |
Dec 07, 2023 | lamond david | bought | 19,314 | 1.01 | 19,123 | - |
Dec 06, 2023 | lamond david | bought | 19,505 | 1.02 | 19,123 | - |
Dec 05, 2023 | lamond david | bought | 19,314 | 1.01 | 19,123 | - |
Dec 01, 2023 | lamond david | bought | 13,515 | 0.94 | 14,378 | - |
Nov 30, 2023 | lamond david | bought | 12,940 | 0.9 | 14,378 | - |
Which funds bought or sold QNCX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -125,728 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -12,604 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 28,043 | 28,043 | -% |
May 15, 2024 | Royal Bank of Canada | added | 68.7 | - | - | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 1,385 | 146,805 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -13,843 | - | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -8.46 | -256,489 | 3,124,510 | 0.32% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -9.7 | -5,519 | 56,900 | -% |
May 15, 2024 | Mariner, LLC | unchanged | - | 740 | 78,518 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -7.56 | -637 | 8,904 | -% |
Unveiling Quince Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Quince Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Quince Therapeutics, Inc. News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -5.1% | 159 | 168 | 85.00 | 89.00 | 93.00 | 104 | 110 | 118 | 116 | 133 | 147 | 161 | 175 | 189 | 205 | 219 | 231 | 124 | 133 | 143 | 71.00 |
Current Assets | -9.0% | 70.00 | 77.00 | 85.00 | 89.00 | 92.00 | 94.00 | 98.00 | 99.00 | 96.00 | 112 | 119 | 136 | 150 | 138 | 143 | 152 | 169 | 106 | 124 | 134 | 64.00 |
Cash Equivalents | 5.1% | 22.00 | 21.00 | 22.00 | 23.00 | 47.00 | 45.00 | 32.00 | 47.00 | 68.00 | 70.00 | 62.00 | 74.00 | 85.00 | 67.00 | 64.00 | 66.00 | 86.00 | 51.00 | 45.00 | 44.00 | 21.00 |
Net PPE | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Goodwill | -2.2% | 17.00 | 18.00 | - | - | - | - | - | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 2.8% | 85.00 | 83.00 | 42.00 | 2.00 | 3.00 | 3.00 | 5.00 | 6.00 | 10.00 | 15.00 | 15.00 | 19.00 | 18.00 | 17.00 | 17.00 | 14.00 | 13.00 | 9.00 | 6.00 | 7.00 | 4.00 |
Current Liabilities | 2.8% | 10.00 | 10.00 | 2.00 | 2.00 | 3.00 | 3.00 | 5.00 | 6.00 | 10.00 | 14.00 | 14.00 | 19.00 | 18.00 | 17.00 | 16.00 | 14.00 | 13.00 | 9.00 | 6.00 | 7.00 | 4.00 |
Long Term Debt | 0.7% | 14.00 | 13.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -12.8% | 74.00 | 85.00 | 83.00 | 87.00 | 90.00 | 101 | 105 | 112 | 106 | 119 | 133 | 142 | 156 | 172 | 188 | 205 | 218 | 115 | 127 | 136 | - |
Retained Earnings | -3.5% | -330 | -319 | -310 | -305 | -300 | -288 | -282 | -274 | -258 | -236 | -213 | -191 | -169 | -146 | -126 | -104 | -86.98 | -69.81 | -57.43 | -47.57 | -38.51 |
Additional Paid-In Capital | 0.4% | 403 | 402 | 393 | 392 | 391 | 389 | 387 | 387 | 365 | 355 | 346 | 333 | 326 | 319 | 314 | 309 | 305 | 185 | 185 | 184 | 0.00 |
Shares Outstanding | 0.6% | 43.00 | 43.00 | 36.00 | 36.00 | 36.00 | 36.00 | 33.00 | 31.00 | 30.00 | 30.00 | 30.00 | 30.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 50.00 | - | - | - | 70.00 | - | - | - | 1,240 | - | - | - | 1,370 | - | - | - | 669 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -37.4% | -8,353 | -6,078 | -4,818 | -3,827 | -3,569 | -5,835 | -6,697 | -15,415 | -16,091 | -14,418 | -17,342 | -17,562 | -13,610 | -13,276 | -12,371 | -14,392 | -10,779 | -10,950 | -8,796 | -6,315 | -7,216 |
Share Based Compensation | 17.3% | 1,274 | 1,086 | 1,331 | 1,322 | 1,481 | 1,632 | 694 | 5,052 | 9,240 | 8,493 | 7,619 | 6,750 | 6,991 | 4,959 | 4,158 | 3,398 | 1,955 | 577 | 912 | 377 | 190 |
Cashflow From Investing | 65.4% | 8,914 | 5,390 | 3,635 | -20,323 | 5,540 | 18,666 | -8,826 | -5,251 | 13,413 | 20,919 | 766 | 5,624 | 31,643 | 15,826 | 10,371 | -5,947 | -72,681 | 17,704 | 9,222 | -47,837 | 3,164 |
Cashflow From Financing | 233.3% | 190 | 57.00 | 10.00 | 26.00 | 50.00 | -18.00 | -5.00 | 108 | 622 | 990 | 4,705 | 672 | 441 | 45.00 | 90.00 | 889 | 117,852 | -530 | - | 77,832 | 64.00 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 3,702 | $ 3,230 |
General and administrative | 4,971 | 3,826 |
Intangible asset impairment charge | 0 | 5,900 |
Fair value adjustment for contingent consideration | 2,545 | 0 |
Total operating expenses | 11,218 | 12,956 |
Loss from operations | (11,218) | (12,956) |
Fair value adjustment for long-term debt | (388) | 0 |
Interest income | 887 | 700 |
Other expense, net | (399) | (246) |
Net loss before income tax benefit | (11,118) | (12,502) |
Income tax (expense) benefit | (31) | 248 |
Net loss | (11,149) | (12,254) |
Other comprehensive loss: | ||
Foreign currency translation adjustments | (1,229) | 92 |
Unrealized gain on available-for-sale securities | 7 | 235 |
Total comprehensive loss | $ (12,371) | $ (11,927) |
Net loss per share - basic | $ (0.26) | $ (0.34) |
Net loss per share - diluted | $ (0.26) | $ (0.34) |
Weighted average shares of common stock outstanding - basic | 43,010,212 | 35,855,200 |
Weighted average shares of common stock outstanding - diluted | 43,010,212 | 35,855,200 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 21,813 | $ 20,752 |
Short-term investments | 46,010 | 54,307 |
Prepaid expenses and other current assets | 2,616 | 2,381 |
Total current assets | 70,439 | 77,440 |
Property and equipment, net | 234 | 234 |
Operating lease right-of-use assets | 576 | 385 |
Goodwill | 17,245 | 17,625 |
Intangible asset | 62,253 | 63,672 |
Other assets | 8,467 | 8,466 |
Equity investments in Lighthouse Pharmaceuticals, Inc. | 78 | 78 |
Total assets | 159,292 | 167,900 |
Current liabilities: | ||
Accounts payable | 2,070 | 2,033 |
Short-term contingent consideration | 4,748 | 4,103 |
Accrued expenses and other current liabilities | 3,020 | 3,436 |
Total current liabilities | 9,838 | 9,572 |
Long-term debt | 13,518 | 13,429 |
Long-term operating lease liability | 480 | 321 |
Long-term contingent consideration | 55,503 | 53,603 |
Deferred tax liabilities | 5,177 | 5,304 |
Other long-term liabilities | 599 | 587 |
Total liabilities | 85,115 | 82,816 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value, 10,000,000 authorized, (100,000 shares of which are designated as Series A Junior Participating Preferred Stock), no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | 0 | 0 |
Common stock, $0.001 par value, 100,000,000 shares authorized, 43,215,233 and 42,973,215 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 43 | 43 |
Additional paid in capital | 403,102 | 401,638 |
Accumulated other comprehensive income | 1,825 | 3,047 |
Accumulated deficit | (330,793) | (319,644) |
Total stockholders’ equity | 74,177 | 85,084 |
Total liabilities and stockholders’ equity | $ 159,292 | $ 167,900 |